Totus Medicines is discovering and developing small molecule medicines using a novel DNA-encoded covalent library technology combined with artificial intelligence/machine learning (AI/ML). With the unprecedented ability to screen billions of drug candidates against thousands of targets simultaneously, the company's novel platform can find drugs that are dramatically superior to molecules discovered through previous technologies, including drug candidates for currently undruggable targets.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/15/23 | $66,000,000 | Series B |
Camford Capital DCVC Northpond Ventures University of Minnesota | undisclosed |
